Status:
RECRUITING
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-te...
Detailed Description
Cilta-cel (JNJ-68284528/LCAR-B38M chimeric antigen receptor T-cells \[CAR-T\]) is an autologous CAR-T therapy that targets B-cell maturation antigen (BCMA), a molecule expressed on the surface of matu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- Participants who have provided informed consent for this study
Exclusion
Key Trial Info
Start Date :
March 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2037
Estimated Enrollment :
295 Patients enrolled
Trial Details
Trial ID
NCT05201781
Start Date
March 9 2022
End Date
October 30 2037
Last Update
December 5 2025
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona, United States, 85054
2
City of Hope
Duarte, California, United States, 91010
3
University of California San Francisco
San Francisco, California, United States, 94143
4
Stanford University Medical Center
Stanford, California, United States, 94305-5623